Related Experiment Videos

Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a

N Cağlar1, I Dincer

  • 1Ibn Sina Hospital, School of Medicine, University of Ankara, Ankara, Turkey. nailcaglar@gmail.com

European Review for Medical and Pharmacological Sciences
|February 1, 2012
PubMed

Insights

Nebivolol significantly reduced left ventricular mass index (LVMI) more than ramipril in hypertensive patients. Both drugs effectively lowered blood pressure, but nebivolol demonstrated superior efficacy in reducing LVMI.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular events in hypertensive patients.
  • Nebivolol and ramipril are commonly prescribed antihypertensive medications with different mechanisms of action.
  • Comparing their effects on LVH is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To compare the efficacy of nebivolol versus ramipril in reducing left ventricular mass index (LVMI) in patients with hypertension and LVH.
  • To assess the impact of both drugs on blood pressure control.

Main Methods:

  • A randomized, blinded endpoint (PROBE) study involving 106 patients with mild-to-moderate hypertension and LVH.
  • Patients received either ramipril (2.5 mg/day) or nebivolol (5 mg/day) for 39 weeks.
  • Left ventricular mass index (LVMI) was measured using echocardiography; blood pressure was monitored regularly.

Main Results:

  • Both nebivolol and ramipril significantly reduced LVMI (p < 0.001).
  • Nebivolol demonstrated a statistically significant greater reduction in LVMI compared to ramipril (p < 0.001).
  • Both treatments achieved similar blood pressure reduction after 39 weeks.

Conclusions:

  • Nebivolol and ramipril effectively decrease LVMI in hypertensive patients.
  • Nebivolol (5 mg/day) is more effective than ramipril (2.5 mg/day) in reducing LVMI.
  • Both drugs provide comparable blood pressure control.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...